BiondVax Pharmaceuticals Ltd.
| NASDAQ: BVXV | Healthcare / Biotechnology / Israel |
| 1.42 | 0 | 0.00 | Vol 1.43K | 1Y Perf 5.97% |
| Jun 9th, 2023 09:30 DELAYED |
| BID | 1.42 | ASK | 1.44 | ||
| Open | 1.42 | Previous Close | 1.42 | ||
| Pre-Market | 1.47 | After-Market | - | ||
| 0.05 3.45% | - - |
| Target Price | 63.50 | Analyst Rating | — 0.00 | |
| Potential % | 4.37K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.90 | Earnings Rating | Neutral | |
| Market Cap | 4.66M | Earnings Date | 7th Jun 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.27 | |
| Beta | 2.46 |
Today's Price Range 1.421.42 | 52W Range 1.3113.50 | 5 Year PE Ratio Range -10.90-2.60 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -16.47% | ||
| 1 Month | -26.80% | ||
| 3 Months | -34.56% | ||
| 6 Months | -87.04% | ||
| 1 Year | 5.97% | ||
| 3 Years | -92.28% | ||
| 5 Years | -77.81% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 539.28 | |||
ROE last 12 Months | -441.41 | |||
ROA (5Y Avg) | -31.43 | |||
ROA last 12 Months | -38.95 | |||
ROC (5Y Avg) | -59.08 | |||
ROC last 12 Months | -27.89 | |||
Return on invested Capital Q | 5.00 | |||
Return on invested Capital Y | -6.25 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.50 | ||||
| 2.15 | ||||
| - | ||||
| - | ||||
| -1.20 | ||||
| -4.39 | ||||
| 2.15 | ||||
| 1.40 | ||||
| 14.82M | ||||
| Forward PE | -9.34 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.80 | ||||
| 5.80 | ||||
| 0.87 | ||||
| 6.63 | ||||
| -1.00 | ||||
| Leverage Ratio | 8.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2023 | - | -1.20 | - |
| Q04 2022 | - | -0.30 | - |
| Q03 2022 | -0.10 | 0.06 | 160.00 |
| Q02 2022 | 0.00 | -2.10 | - |
| Q01 2022 | 0.00 | -2.00 | - |
| Q04 2021 | -0.10 | 0.00 | 100.00 |
| Q02 2021 | - | -3.70 | - |
| Q04 2020 | - | -0.36 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2023 QR | 0.00 | 100.00 | Positive |
| 9/2023 QR | 0.00 | 100.00 | Positive |
| 12/2023 FY | -0.01 | - | - |
| 12/2024 FY | 0.00 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.43K |
| Shares Outstanding | 3.28K |
| Shares Float | 3.28M |
| Trades Count | 25 |
| Dollar Volume | 2.00K |
| Avg. Volume | 739.14K |
| Avg. Weekly Volume | 1.68M |
| Avg. Monthly Volume | 387.14K |
| Avg. Quarterly Volume | 153.41K |
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) stock closed at 1.42 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 52.24K shares and market capitalization of 4.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. BiondVax Pharmaceuticals Ltd. CEO is Ron Babecoff.
The one-year performance of BiondVax Pharmaceuticals Ltd. stock is 5.97%, while year-to-date (YTD) performance is -52.03%. BVXV stock has a five-year performance of -77.81%. Its 52-week range is between 1.31 and 13.5, which gives BVXV stock a 52-week price range ratio of 0.90%
BiondVax Pharmaceuticals Ltd. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 2.15, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.95%, a ROC of -27.89% and a ROE of -441.41%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BiondVax Pharmaceuticals Ltd., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BiondVax Pharmaceuticals Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BiondVax Pharmaceuticals Ltd. is — (0), with a target price of $63.5, which is +4 371.83% compared to the current price. The earnings rating for BiondVax Pharmaceuticals Ltd. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BiondVax Pharmaceuticals Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BiondVax Pharmaceuticals Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.12, ATR14 : 0.15, CCI20 : -209.86, Chaikin Money Flow : -0.89, MACD : -0.12, Money Flow Index : 94.59, ROC : -23.24, RSI : 26.41, STOCH (14,3) : 11.46, STOCH RSI : 0.00, UO : 23.61, Williams %R : -88.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BiondVax Pharmaceuticals Ltd. in the last 12-months were:
BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.
CEO: Ron Babecoff
Telephone: +972 89302529
Address: Hadassah Ein Kerem Campus, Jerusalem 74036, , IL
Number of employees: 25
